Intuit Inc. vs GeneDx Holdings Corp — how do they compare? Intuit Inc. trades at $289.3 (market cap $80.37B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Intuit Inc. is far larger — about 44.6× GeneDx Holdings Corp's market cap, and Intuit Inc. pays a 1.63% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| INTU | WGS | |
|---|---|---|
Market Cap | $80.37B | $1.80B |
Sector | Technology | Technology |
52-Week High | $807.39 | $167.51 |
52-Week Low | $255.07 | $34.51 |
Enterprise Value | $78.83B | $1.80B |
Dividend Yield | 1.63% | — |
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $291.09, down 1.26% over the past day, amid mixed technical signals and ongoing legal scrutiny. The stock shows strong fundamentals with revenue growth from $18.83B in 2025 to a projected $20.9B in 2026, net income margin improving to 21.91%, and consistent earnings beats. However, recent news highlights a 20% stock drop and multiple securities fraud investigations related to TurboTax pricing issues, creating investor uncertainty despite a bullish analyst consensus.
The outlook for INTU is cautiously optimistic given its robust financial health and AI-driven growth initiatives, but near-term risks from legal challenges and market sentiment could pressure the stock. Investors should weigh the company's solid profitability and upward earnings trajectory against potential volatility from ongoing investigations and competitive pressures in the fintech software space.
No Aura AI signal available yet.
Trailing returns across standard periods
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →